Eleanor Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Outpatient addiction and mental health treatment platform, Boston MA, raised $50M+. Value-based care model integrating SUD treatment with mental health support.
About
Eleanor Health is a Boston, Massachusetts-based behavioral health company founded in 2019 that provides value-based outpatient treatment for substance use disorder (SUD) combined with mental health care. The company has raised over $50 million and operates in multiple states through a hybrid model that combines telehealth with community-based care hubs staffed by multidisciplinary care teams. Eleanor Health treats addiction to opioids, alcohol, and other substances alongside co-occurring mental health conditions such as depression, anxiety, and PTSD.\n\nEleanor Health's care model is built around value-based contracts with Medicaid managed care organizations and commercial health plans, aligning the company's financial incentives with patient outcomes rather than visit volume. Care teams include addiction medicine specialists, therapists, care coordinators, and community health workers who support patients through recovery with a whole-person approach. The platform integrates medication-assisted treatment (MAT), individual and group therapy, and social needs navigation into a coordinated care program.\n\nThe company focuses on serving Medicaid populations with high rates of co-occurring substance use and mental health conditions, a population that historically experiences fragmented care across separate addiction and mental health service systems. Eleanor Health's integrated model is designed to reduce emergency department utilization, hospitalizations, and crisis episodes among high-need members. The company has partnered with several state Medicaid programs and commercial payers to expand access to its model across the Southeast and other regions.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.